Bristol-Myers Squibb Company
345 Park Avenue
New York
New York
10154
United States
Tel: 212-546-4000
Fax: 212-546-4020
Website: http://www.bms.com/
About Bristol-Myers Squibb Company
Bristol-Myers Squibb is a global biopharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
1958 articles with Bristol-Myers Squibb Company
-
A combination of Opdivo and Yervoy yielded a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) than patients who were treated with sunitinib, the standard of care.
-
Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer
10/20/2018
Bristol-Myers Squibb Company (NYSE: BMY) today announced follow-up data evaluating Opdivo (nivolumab) monotherapy and Opdivo in combination with Yervoy (ipilimumab) in patients with platinum-pretreated metastatic urothelial carcinoma (mUC)
-
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
-
Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting
10/17/2018
Growing body of evidence, including real-world studies, points to the clinical significance of anti-citrullinated protein antibody (ACPA) as a biomarker of poor prognosis in patients with rheumatoid arthritis (RA)
-
Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer
10/12/2018
Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin
-
Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo failed to meet endpoints as a treatment option for small cell lung cancer (SCLC) patients who relapsed following platinum-based chemotherapy.
-
Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen
10/11/2018
Bristol-Myers Squibb Company and Compugen today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701
-
Nobel Prizes Underscore Benefits of Research, but Also Highlight ‘Worst Instincts’ of Industry: R...
10/9/2018
In a report, Bloomberg said that pharma’s “efforts to maximize (financial) gains” has led to the coloring of R&D decisions and creating barriers to the entry of competing medications that can add costs to the health care system. -
CLSA Names Pantheon DiNA Award Winners
10/9/2018
Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association. -
Why Does Immunotherapy Cost So Much?
10/4/2018
As cancers develop treatment resistance, combinations of old and new therapies will become increasingly important to effective treatment. The use of multiple, potentially costly, drugs during combination therapy, increased duration of novel therapies and the possibility of patients needing multip... -
Memorial Sloan Kettering's Chief Executive Officer Craig Thompson has resigned from the boards of directors at Merck and Charles River Labs as the cancer center continues to be scrutinized for its ties to the pharmaceutical industry.
-
Despite winning regulatory approval for a copycat version of Copaxone earlier this year, Cambridge, Mass.-based Momenta Pharmaceuticals has completed a strategic review that includes slashing its staff by 50 percent as the company focuses its resources on two biosimilar candidates in its pipeline.
-
3 Months After Launching a Phase Ib Trial, Janssen Terminates Collaboration Deal with Aduro Biotech
10/2/2018
Janssen Biotech, a Johnson & Johnson company, informed Aduro Biotech that it was terminating its research and license deals related to Aduro’s Listeria treatment for cancers. -
Harnessing the body’s own immune system to fight cancer has been one of the key focuses of drugmakers over the past several years. This year, the Nobel committee recognized two research pioneers for their trailblazing efforts in this field.
-
Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.
-
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
-
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
-
A three-year-old cancer research alliance between U.S. and Cuban scientists is bearing fruit. A Cuban-developed lung cancer treatment combined with Opdivo shows promise in treating patients.
-
This morning, Genentech released results of its Phase III IMpower 133 trial that showed treatment with Tecentriq plus chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer than with chemotherapy alone.
-
AstraZeneca and its MedImmune division released data on overall survival (OS) in its Phase III PACIFIC clinical trial of Imfinzi (durvalumab).